Assets of Molecular Diagnostics Company

Sale of substantially all of assets of Lexagene Inc. (the “Seller”), which includes:

• The operations, parts, equipment, furniture, fixtures, leasehold improvements, products, designs, patent rights, patent applications, licenses, intellectual property, and technologies with respect to in-clinic PCR testing for pathogens and drug resistant genes and other businesses engaged in by the seller on or before the Petition Date including, without limitation, (i) the assets required to develop, manufacture, test, and deliver (A) laboratory testing equipment known as the MiQLab System and (B) related sample preparation cartridges and reagent panels, and (ii) those assets listed on Schedule 1.1(a) of the Agreement (collectively, the “Business”);
• All contracts listed on Schedule 1.1(b) of the Agreement, including the Lease (the “Assumed Contracts”);
• To the maximum extent permitted by Law, all licenses, franchises, permits, certificates, approvals, and authorizations from Governmental Bodies necessary for operation and ownership of the Acquired Assets (collectively, “Permits”);
• any prepayments or good faith or other deposits, including by customers
• for unfulfilled orders covered by Assumed Contracts;
• All books and records of the Business (except as set forth in Section 1.3(a) of the Agreement);
• All recoveries from insurance policies related solely to the Acquired Assets and any rights to assert claims seeking any such recoveries related solely to the Acquired Assets; and
• Claims of the Trustee on behalf of the seller's bankruptcy estate against Meridian, other than as related to this Agreement.